As Teva's Neurology Portfolio Gains Momentum, New Assets Join The Pipeline
Q3 results show Austedo appears headed towards blockbuster status, and the company signed a collaboration with MODAG for two compounds for neurodegenerative diseases.
You may also be interested in...
Aurobindo Matches Lupin With Teva Austedo Settlement
Aurobindo has settled US patent litigation with Teva over Austedo, giving the Indian company an April 2033 launch date for generic deutetrabenazine, matching the date gained by Lupin in an earlier settlement.
Lupin Lines Up Rival To Teva’s Austedo – But Not Until 2033
Lupin will be able to launch a deutetrabenazine generic rival to Teva’s Austedo brand in the US from 2033, following a settlement agreement between the two firms. However, Aurobindo is continuing to fight a patent-infringement suit with the Israeli firm.
Lilly’s Alzheimer’s Drug Will Get ‘Easier Ride’ Than Aduhelm But Does Not Show Clinical Benefit, Prof Says
Harsh assessment of Lilly’s Phase II study by UCL and UCSF professors suggests donanemab may face same hurdles as Biogen’s Aduhelm. Lilly exec says the drug slowed disease progression by six months, but UCL prof says that won’t make a difference.